pneumonia
lead
caus
hospit
among
adult
children
unit
state
account
hospit
emerg
depart
visit
among
expens
condit
treat
us
hospit
nation
aggreg
cost
billion
causal
pathogen
often
identifi
prospect
multicent
studi
center
diseas
control
prevent
identifi
respons
pathogen
case
communityacquir
pneumonia
cap
adult
requir
hospit
cap
infect
lung
parenchyma
acquir
outsid
hospit
extendedcar
facil
viral
pathogen
identifi
case
bacteri
pathogen
case
adult
age
human
rhinoviru
influenza
frequent
identifi
virus
streptococcu
pneumonia
common
causal
bacterium
staphylococcu
aureu
enterobacteriacea
significantli
common
among
patient
requir
intens
care
unit
icu
level
care
bacteria
identifi
cap
includ
mycoplasma
pneumonia
chlamydophila
pneumonia
haemophilu
influenza
less
common
bacteri
caus
includ
mycobacterium
tuberculosi
legionella
sp
pseudomona
aeruginosa
bacteria
may
consid
like
patient
certain
risk
factor
tabl
diagnosi
diagnosi
pneumonia
consid
patient
present
acut
onset
fever
chill
cough
cough
may
describ
product
addit
symptom
frequent
seen
includ
fatigu
anorexia
pleurit
chest
pain
import
compon
histori
includ
recent
travel
histori
underli
lung
diseas
smoke
histori
studi
diehr
colleagu
found
histori
alcohol
bloodi
sputum
rel
risk
presenc
find
predict
pneumonia
physic
examin
find
frequent
appreci
patient
pneumonia
includ
decreas
breath
sound
rale
tactil
fremitu
crackl
tachypnea
hypotens
worrisom
symptom
may
also
seen
requir
urgent
evalu
imper
maintain
high
level
suspicion
immunocompromis
elderli
nurs
home
patient
frequent
display
fewer
overt
symptom
pneumonia
compar
gener
popul
individu
compon
histori
physic
examin
use
diagnos
pneumonia
presenc
multipl
find
requir
tabl
adult
present
acut
cough
baselin
probabl
pneumonia
absenc
vital
sign
abnorm
blood
pressur
heart
rate
respiratori
rate
reduc
predict
probabl
pneumonia
chest
radiograph
order
patient
abnorm
vital
sign
defin
temperatur
higher
f
heart
rate
higher
bpm
respiratori
rate
higher
bpm
imag
also
obtain
physic
examin
abnorm
crackl
decreas
breath
sound
patient
without
asthma
infecti
diseas
societi
america
guidelin
recommend
imag
demonstr
infiltr
confirm
diagnosi
pneumonia
exclud
caus
cough
fever
acut
bronchiti
although
xray
imag
mainstay
diagnosi
pneumonia
british
thorac
societi
recommend
entir
clinic
pictur
consid
make
decis
treat
systemat
review
found
among
patient
sick
enough
admit
clinic
diagnosi
cap
normal
initi
chest
radiograph
approxim
develop
radiograph
evid
pneumonia
within
hour
case
appropri
treat
patient
empir
pneumonia
repeat
imag
hour
commun
resourc
access
imag
may
also
affect
decis
treat
without
imag
routin
blood
sputum
cultur
test
costli
often
lowyield
howev
extens
diagnost
test
consid
patient
risk
infect
unusu
pathogen
respond
treatment
addit
test
like
chang
antibiot
manag
tabl
reason
consid
respiratori
viral
polymeras
chain
reaction
pcr
determin
viral
caus
symptom
inappropri
antibiot
use
limit
addit
test
tuberculosi
consid
patient
present
persist
cough
particularli
set
weight
loss
malais
night
sweat
hemoptysi
addit
risk
factor
tuberculosi
tb
includ
immigr
endem
countri
resid
homeless
shelter
intraven
drug
use
human
immunodefici
viru
hiv
infect
person
work
peopl
high
risk
tb
infect
also
consid
high
risk
treatment
case
pneumonia
manag
outpati
set
sever
sever
assess
tool
develop
help
determin
appropri
treatment
set
pneumonia
sever
index
psi
consid
variabl
stratifi
patient
risk
categori
iv
base
risk
death
within
day
given
number
paramet
requir
frequent
use
gener
practic
assess
tool
introduc
british
thorac
societi
similar
psi
calcul
risk
mortal
instead
use
variabl
confus
urea
respiratori
rate
blood
pressur
age
one
point
award
present
allow
greater
eas
use
calcul
without
blood
urea
thu
use
outpati
set
recent
systemat
review
metaanalysi
found
signific
differ
test
perform
compar
sever
tool
note
psi
neg
likelihood
ratio
suggest
may
superior
identifi
lowrisk
patient
may
superior
identifi
highrisk
patient
score
demonstr
low
risk
mortal
suggest
patient
manag
outpati
set
score
higher
warrant
hospit
admiss
alway
appropri
consid
patient
social
circumst
treatment
wish
make
treatment
decis
fig
score
avail
treatment
cap
guid
local
resist
pattern
previous
healthi
patient
appropri
outpati
treatment
recommend
firstlin
treatment
macrolid
antibiot
azithromycin
target
common
causal
pathogen
pneumonia
doxycyclin
altern
option
patient
comorbid
diabet
chronic
heart
lung
renal
liver
diseas
alcohol
asplenia
impair
immun
system
recent
antibiot
use
within
last
month
increas
risk
drugresist
pneumonia
respiratori
fluoroquinolon
blactam
plu
macrolid
recommend
tabl
cochran
review
found
signific
differ
efficaci
antibiot
regimen
although
differ
advers
effect
compar
antibiot
within
singl
class
patient
appropri
inpati
nonicu
treatment
also
treat
respiratori
fluoroquinolon
macrolid
blactam
patient
treat
minimum
day
clinic
stabl
resolv
symptom
treatment
discontinu
patient
high
sever
infect
extrapulmonari
manifest
may
benefit
longer
durat
therapi
day
improv
recent
year
emerg
data
support
use
adjunct
corticosteroid
inpati
treatment
cap
area
research
multipl
recent
systemat
review
metaanalys
publish
conflict
find
cochran
review
includ
relev
cap
studi
year
show
corticosteroid
use
acceler
time
symptom
resolut
clinic
stabil
infrequ
advers
effect
similarli
systemat
review
siemieniuk
colleagu
includ
studi
analysi
random
control
trial
found
significantli
decreas
mortal
sever
pneumonia
decreas
need
mechan
ventil
decreas
occurr
acut
respiratori
distress
syndrom
decreas
time
clinic
stabil
shorter
durat
hospit
hyperglycemia
requir
treatment
occur
frequent
patient
treat
corticosteroid
recent
idsa
bt
guidelin
make
recommend
regard
routin
use
adjunct
corticosteroid
cap
given
variat
dose
rout
administr
optim
agent
dose
unknown
research
need
determin
steroid
dose
durat
well
patient
popul
like
benefit
use
larg
number
studi
assess
role
infect
biomark
procalcitonin
diagnosi
monitor
patient
bacteri
infect
cochran
metaanalysi
primari
care
set
conclud
use
procalcitonin
guid
initi
durat
antibiot
treatment
result
lower
risk
mortal
lower
antibiot
consumpt
lower
risk
antibioticrel
side
effect
procalcitonin
valu
low
high
usual
exclud
bacteri
infect
alway
per
practition
discret
depend
patient
complex
comorbid
followup
appoint
success
manag
primari
care
set
may
arrang
appoint
repeat
xray
imag
confirm
resolut
pneumonia
indic
patient
seem
clinic
well
patient
persist
symptom
high
risk
lung
cancer
age
pack
year
smoke
histori
repeat
xray
imag
lowdos
computer
tomographi
ct
scan
screen
lung
cancer
consid
unit
state
pneumococc
conjug
vaccin
recommend
babi
children
younger
year
adult
age
year
older
well
children
adult
age
year
year
increas
risk
pneumococc
diseas
due
certain
medic
condit
pneumococc
conjug
vaccin
shown
observ
reduct
vaccinetyp
pneumococc
cap
persist
least
year
receiv
vaccin
pneumococc
polysaccharid
vaccin
pneumovax
recommend
adult
age
year
older
cigarett
smoker
age
year
well
children
adult
age
year
certain
medic
condit
cochran
review
found
polysaccharid
vaccin
effect
prevent
invas
pneumococc
diseas
healthi
adult
vaccin
efficaci
howev
poorer
adult
chronic
ill
pneumonia
consid
nonresolv
inadequ
clinic
respons
despit
antibiot
treatment
incid
treatment
failur
associ
increas
mortal
idsa
broadli
classifi
nonrespons
differ
group
progress
pneumonia
character
clinic
deterior
persist
pneumonia
absenc
delay
clinic
stabil
progress
pneumonia
deterior
character
respiratori
failur
septic
shock
typic
occur
within
hour
persist
pneumonia
absent
delay
respons
typic
consid
time
period
hour
often
regard
median
time
requir
clinic
stabil
concern
nonrespons
patient
pneumonia
initi
systemat
evalu
possibl
caus
host
factor
may
explain
poor
respons
consid
includ
high
initi
sever
score
risk
factor
infect
unusu
organ
underli
comorbid
risk
factor
multidrugresist
pathogen
tabl
area
high
preval
hiv
tb
test
recommend
result
initi
microbiolog
test
blood
sputum
cultur
review
includ
sensit
data
repeat
blood
cultur
obtain
set
clinic
deterior
addit
laboratori
test
pneumonia
legionella
pneumophila
via
urin
antigen
test
may
perform
may
remain
posit
day
initi
antibiot
treatment
addit
imag
chest
ct
may
benefici
assess
interv
progress
improv
identifi
pleural
effus
lung
abscess
pulmonari
embol
pleural
effus
identifi
patient
treatment
failur
thoracentesi
perform
evalu
empyema
select
patient
bronchoscopi
protect
bronchial
sampl
bronchoalveolar
lavag
bal
may
benefici
provid
diagnost
inform
infecti
caus
noninfecti
mimic
pulmonari
eosinophilia
druginduc
pneumon
sarcoidosi
pulmonari
fibrosi
primari
metastat
neoplast
lesion
obstruct
bronchu
may
caus
accumul
secret
distal
obstruct
predispos
infect
hodgkin
nonhodgkin
lymphoma
present
lung
involv
typic
radiograph
find
hilar
mediastin
adenopathi
may
also
present
pattern
suggest
infect
elderli
patient
pneumonia
may
exhibit
typic
symptom
physic
examin
find
seen
younger
adult
pleurit
chest
pain
cough
fever
leukocytosi
sign
symptom
frequent
seen
older
adult
includ
fall
decreas
appetit
function
impair
chang
mental
statu
prompt
evalu
infecti
caus
adult
risk
factor
atyp
drugresist
pathogen
guid
treatment
elderli
patient
histori
stroke
known
dysphagia
increas
risk
aspir
pneumonia
resid
nurs
home
longterm
care
facil
increas
risk
methicillinresist
staphylococcu
aureu
mrsa
multidrugresist
mdr
pathogen
evalu
return
travel
includ
follow
appropri
histori
cover
travel
itinerari
locat
activ
onset
ill
relat
travel
vaccin
prophylaxi
receiv
diet
sexual
histori
exposur
anim
respiratori
tract
infect
among
common
health
care
complaint
affect
return
travel
diagnos
return
patient
fever
although
upper
respiratori
tract
infect
common
sever
possibl
mortal
associ
lower
respiratori
tract
infect
pneumonia
make
mustnotmiss
diagnosi
return
travel
unit
state
pneumonia
h
influenza
aureu
domin
pneumonia
isol
develop
countri
must
consid
bacteri
resist
pattern
differ
countri
may
differ
otherwis
commonplac
bacteria
respiratori
symptom
occur
half
patient
malaria
present
may
seem
similar
pneumonia
thu
patient
return
malariaendem
area
blood
smear
test
malaria
perform
increas
time
spent
hotel
cruis
ship
patient
present
symptom
pneumonia
increas
suspicion
legionella
travel
return
east
southeast
asia
well
australia
sever
pneumonia
may
expos
burkholderia
pseudomalleith
caus
agent
melioidosi
caus
sever
necrot
pneumonia
mortal
despit
appropri
antibiot
therapi
sever
pneumonia
may
also
virus
influenza
middl
eastern
respiratori
syndrom
hantaviru
return
travel
pneumonia
eosinophilia
rais
suspicion
helminth
infect
histoplasma
capsulatum
dimorph
fungu
rel
common
north
central
south
america
given
growth
bird
bat
drop
associ
activ
cave
explor
coccidioid
immiti
endem
southwest
unit
state
northern
mexico
well
smaller
area
central
america
spread
inhal
spore
found
soil
fungal
infect
h
capsulatum
c
immiti
often
asymptomat
may
also
present
flulik
ill
fever
malais
dri
cough
week
exposur
ventilatorassoci
pneumonia
ventilatorassoci
pneumonia
vap
type
pneumonia
occur
patient
intub
mechan
ventil
mean
tracheostomi
least
hour
mechan
ventil
modifi
oropharyng
tracheal
environ
allow
oral
gastric
secret
enter
lower
airway
chang
lower
respiratori
tract
bacteri
flora
precipit
begin
pneumonia
vap
common
approxim
patient
receiv
mechan
ventil
develop
vap
vap
suspect
sign
pulmonari
infect
fever
purul
secret
leukocytosi
radiolog
evid
air
bronchogram
infiltr
present
bacteriolog
confirm
usual
follow
sensit
specif
diagnost
criteria
discuss
earlier
respect
use
diagnost
criteria
develop
incorpor
addit
symptom
similar
sign
laboratoryradiolog
criteria
vap
clinic
suspect
earli
empir
treatment
favor
delay
treatment
andor
appropri
cover
like
microbi
culprit
associ
higher
morbid
mortal
microbiolog
microbi
organ
associ
vap
identifi
tabl
earli
versu
lateonset
vap
organ
also
document
acinetobact
citrobact
pseudomona
klebsiella
predomin
lateonset
organ
warrant
aggress
antibacteri
intervent
bacteri
confirm
usual
requir
secret
sampl
either
via
bronchoscop
via
nonbronchoscop
method
obtain
pleural
fluid
present
ultrasound
guidanc
recommend
endotrach
aspir
easili
retriev
high
falseposit
rate
icu
patient
due
airway
colon
bronchoscop
retriev
distal
airway
specimen
via
bal
protectedspecimen
brush
techniqu
best
requir
train
bronchoscopist
select
antibiot
typic
done
empir
base
whether
patient
risk
factor
mdr
pathogen
tabl
whether
onset
vap
earli
defin
within
first
day
icu
late
day
later
evalu
treatment
pneumonia
empir
treatment
also
determin
result
knowledg
local
distribut
pathogen
antimicrobi
suscept
pattern
earlyonset
vap
without
mdr
risk
factor
typic
prescrib
one
follow
antibiot
option
lateonset
andor
mdr
factor
patient
appropri
antibiot
option
would
includ
one
follow
antipseudomon
cephalosporin
eg
cefepim
ceftazidim
antipseudomon
carbapenem
imipenem
meropenem
betalactambetalactamas
inhibitor
piperacillintazobactam
antipseudomon
fluoroquinolon
ciprofloxacin
aminoglycosid
plu
linezolid
vancomycin
mrsa
risk
factor
present
telavancin
indic
vap
suscept
isol
aureu
therapi
suitabl
dose
frequenc
administr
antibiot
choic
discuss
earlier
document
extens
elsewher
atyp
antibiot
choic
colistin
polymyxin
b
telavancin
inter
alia
rare
indic
use
antimicrobi
resist
warrant
agent
typic
consult
infecti
diseas
physician
clinic
pharmacist
expertis
familiar
use
drug
sine
qua
non
pediatr
pneumonia
epidemiolog
pneumonia
common
afflict
childhood
pneumonia
account
infecti
ill
infant
toddler
younger
year
worldwid
approxim
million
new
case
pneumonia
occur
annual
among
children
younger
year
pneumonia
lead
caus
death
children
younger
year
develop
countri
account
death
children
younger
year
kill
children
childhood
pneumonia
cp
treat
outpati
set
rate
hospit
cp
age
year
vari
per
year
per
infant
younger
year
highest
rate
hospit
per
wherea
children
age
year
lowest
rate
per
sign
symptom
cp
often
nonspecif
depend
sever
factor
includ
age
microbi
organ
underli
health
patient
clinic
acumen
key
success
diagnos
cp
univers
symptom
cp
cough
symptom
may
includ
chest
pain
headach
arthralgia
nausea
abdomin
pain
common
sign
look
includ
fever
tachypnea
labor
breath
rhonchi
crackl
wheez
physic
sign
identifi
includ
grunt
nasal
flare
chest
retract
increas
likelihood
cp
diagnost
test
usual
perform
avail
would
includ
assess
oxygen
satur
puls
oximetri
chest
radiograph
complet
blood
cell
count
respiratori
microbi
panel
pcr
ultrasound
chest
medic
indic
cultur
disagr
whether
blood
cultur
warrant
exist
literatur
per
recent
studi
blood
cultur
shown
assist
clinic
manag
children
hospit
pneumonia
infecti
diseas
societi
america
howev
recommend
blood
cultur
hospit
children
pneumonia
etiolog
microbi
organ
differ
depend
age
child
infant
toddler
preschool
virus
predomin
tabl
less
common
bacteri
organ
may
infect
newborn
see
tabl
older
children
bacteria
common
culprit
tabl
atyp
organ
may
involv
children
immunocompromis
underli
comorbid
see
tabl
order
provid
optim
care
child
pneumonia
import
determin
sever
pneumonia
child
clinic
statu
children
requir
inpati
admiss
criteria
exist
help
stratifi
sever
pneumonia
necess
hospit
box
choos
antibiot
cp
initi
alway
empir
process
base
local
region
microbi
suscept
resist
pattern
along
child
age
immun
statu
underli
preexist
health
condit
children
treat
oral
antibiot
outpati
set
firstlin
prefer
agent
still
amoxicillin
altern
agent
cephalosporin
macrolid
antibiot
howev
increas
resist
penicillin
deriv
macrolid
note
children
infant
concern
care
observ
home
unabl
compli
therapi
unabl
followedup
children
infant
respiratori
distress
hypoxemia
oxygen
satur
see
tabl
children
infant
comorbid
eg
asthma
cystic
fibrosi
congenit
heart
diseas
diabet
mellitu
neuromuscular
diseas
poor
feed
andor
sign
dehydr
link
develop
childhood
tendonitistendinopathi
yet
recent
literatur
indic
disabl
side
effect
rare
inpati
treatment
guidelin
also
establish
tabl
isol
particular
microbi
organ
ideal
requir
order
determin
durat
therapi
uncompl
pneumonia
treatment
outpati
set
usual
last
day
inpati
admiss
pneumonia
warrant
longer
durat
antibiot
therapi
typic
day
combin
parenter
oral
therapi
least
week
becom
afebril
complic
case
pneumonia
requir
minimum
week
therapi
lack
fever
confirm
may
extend
week
switch
parenter
oral
therapi
may
occur
hour
document
lack
fever
alway
practic
complic
icuadmit
patient
pneumonia
common
wellrecogn
respiratori
infect
seen
primari
care
set
triag
usual
present
symptom
gener
set
motion
typic
cours
action
includ
physic
examin
possibl
imag
confirm
clinic
suspicion
test
depend
treatment
venu
outpati
vs
inpati
specif
criteria
see
tabl
empir
antibiot
therapi
cornerston
treatment
knowledg
local
region
microbi
suscept
resist
bolster
success
rate
outpati
manag
pneumonia
regardless
demograph
andor
accompani
morbid
special
circumst
scenario
may
occur
includ
nonresolv
pneumonia
pediatr
geriatr
popul
travelrel
infect
among
other
necessit
care
attent
histori
physic
examin
antibiot
select
